CRA was engaged by a leading global medical device company to provide global transfer pricing advisory. CRA has been instrumental in all parts of its transfer pricing analyses, including IP onshoring, planning, global documentation compliance, audit support, quarterly/year-end support as needed.
US Tax Court favors unspecified method to determine royalty rate
The first US transfer pricing court decision of 2022 was published on Thursday, August 18, 2022, specifically Medtronic, Inc. and Consolidated Subsidiaries v....